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Introduction
Our group recently validated urinary chitinase 3-like pro-
tein 1 (UCHI3L1) as novel biomarker for acute kidney
injury (AKI) in septic mice [1].
Objectives
This ensuing study aimed to investigate whether our pre-
clinical finding could be translated to humans and whether
UCHI3L1 performed equally to the AKI biomarker urinary
neutrophil gelatinase-associated lipocalin (UNGAL) [2].
Methods
Prospective cohort study at the surgical and medical
ICUs of the University Hospital Ghent from Sept. 2012
till Aug. 2014. Patients were included if: age ≥18 y;
arterial and urinary catheter present; expected ICU stay
≥48 h; and respiratory or cardiovascular SOFA score ≥2
resp. ≥1. Participation was excluded if: AKI KDIGOFull
stage ≥2 at inclusion; chronic kidney disease stage 5; or
no written informed consent.
Blood and urine were collected at inclusion. Each
patient was sampled a 2nd time at 6 pm if the 1st collec-
tion was before noon, then at 6 am and pm on days 2-4,
and at 6 am on days 5-7. The study stopped if the patient
was discharged from the ICU before day 7. Reference
serum creatinine (SCr) was defined as the lowest SCr
value within the last 3 months prior to enrollment.
The primary endpoint was AKI KDIGOFull stage ≥2
within 12 h after enrollment. Secondary endpoints were:
AKI KDIGOFull stage ≥2 within 24 h and 7 d after
† Contributed equally
1Ghent University, Laboratory of Biochemistry, Department of Pharmacology,
Toxicology and Biochemistry, Faculty of Veterinary Medicine, Merelbeke,
Belgium
Full list of author information is available at the end of the article
Figure 1
De Loor et al. Intensive Care Medicine Experimental 2015, 3(Suppl 1):A840
http://www.icm-experimental.com/content/3/S1/A840
© 2015 De Loor et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
enrollment; and AKI KDIGOSCr stage ≥2 within 12 h, 24
h and 7 d after enrollment.
Results
In total 181 patients were included, of which 6 (3%)
reached the primary endpoint. Baseline characteristics
showed no differences with the exception of age (70.5 y
[IQR: 65.8-78.0] vs. 59.0 [50.0-70.0] for endpoint pos.
resp. neg.; P = 0.040). At ICU admission, the only signif-
icant difference was the proportion of patients referred
from another department (66.7 vs. 22.3% for endpoint
pos. resp. neg.; P = 0.029).
Both UCHI3L1 and UNGAL measured at inclusion
were good predictors of the primary endpoint, with an
AUC-ROC of 0.792 (95% CI: 0.726-0.849) resp. 0.748
(0.678-0.810). The difference between both areas was
not significant (P = 0.587). Results for all endpoints are
shown in Figure 1.
Conclusions
UCHI3L1 was a valuable diagnostic biomarker for mod-
erate or severe AKI in this adult ICU cohort, and per-
formed similar to UNGAL.
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